Revelation Biosciences, Inc. (REVB)

USD 0.34

(1.75%)

Market Cap (In USD)

2.86 Million

Revenue (In USD)

-

Net Income (In USD)

-120.25 Thousand

Avg. Volume

1.65 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.32-25.26
PE
-
EPS
-
Beta Value
0.153
ISIN
US76135L5075
CUSIP
76135L101
CIK
1810560
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. James M. Rolke
Employee Count
-
Website
https://www.revbiosciences.com
Ipo Date
2020-11-17
Details
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.